Generic Name and Formulations:
Pentavalent, live rotavirus vaccine; oral susp; contains fetal bovine serum (trace); preservative-free.
Merck & Co., Inc.
Indications for ROTATEQ:
Rotavirus gastroenteritis vaccination in infants 6–32 weeks of age.
<6 weeks or >32 weeks: not established. Each dose is 1 tube. Give 1st dose orally at 6–12 weeks of age; give 2nd and 3rd dose at 4–10 week intervals for a total of 3 doses. If incomplete dose is given, do not give replacement dose; continue with remaining doses in the recommended series.
Severe combined immunodeficiency disease. History of intussusception.
Immunocompromised (blood dyscrasias, leukemia, lymphomas, or other malignancies; primary and acquired immunodeficiency states, HIV/AIDS; cellular immune deficiencies; and hypogammaglobulinemic and dysgammaglobulinemic states; received blood transfusion or blood products, including immunoglobulins within 42 days). Febrile illness. Active or history of GI disorders. Chronic diarrhea. Failure to thrive. History of congenital abdominal disorders. Abdominal surgery. Risk of intussusception. Immunodeficient close contacts. Pregnancy (Cat. C), women of child-bearing potential: not recommended.
Immunosuppressants (eg, irradiation, chemotherapy, high-dose steroids): may get suboptimal response. Concomitant vaccines: see full labeling; oral polio vaccine: not recommended.
Diarrhea, vomiting, irritability, otitis media, nasopharyngitis, bronchospasm; rare: intussusception, hematochezia, seizures, Kawasaki disease.
Single-use tube (2mL)—10, 25
Clinical Pain Advisor Articles
- Manual Therapy vs Opioids for Management of Shoulder, Spine Pain
- Kinesiophobia May Be Associated With Greater Cutaneous Allodynia in Migraine
- Intervention by Pharmacists May Effectively Reduce Use of Inappropriate Medications in the Elderly
- PainDETECT May Not Be Optimal to Detect Neuropathic Components of Orofacial Pain
- Topical Migraine Trigger Point Treatment as Effective as Injection
- Serum Vitamin D Levels and Risk for Migraine
- Rimegepant Orally Dissolving Formulation Provides Rapid Relief From Acute Migraine
- Updated Evidence-Based Recommendations for Buprenorphine Treatment
- Prescription Digital Therapeutic Approved for Opioid Use Disorder
- Persistence of Post-Traumatic CRPS Associated With Initial Pain Sensitization
- Blunted Cardiovascular Stress Reactivity in Fibromyalgia With Comorbid PTSD
- Name-Brand Medications Driving Spike in U.S. Drug Spending
- Physician Responsibility to Combat "Fake News" in Medicine
- The Future Of Robot Physicians: Is Artificial Intelligence Poised to Take Over Medicine?
- Chronic Spinal Pain and Depression: Does One Represent a Risk Factor for the Other?